ArticleJournal of neurology2026
Medication use trajectories in myasthenia gravis pregnancies: a population-based drug utilization study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo examine medication use trajectories from 1 year before pregnancy to 6 months postpartum in a population-based birth cohort of patients with myasthenia gravis (MG).
methodsWe used harmonized and pooled national register data from Norway and Sweden (1994-2023) to identify MG pregnancies. Longitudinal dispensing records of symptomatic MG medications, oral corticosteroids (OCS), and non-steroidal immunosuppressant therapy (NSIST) were extracted from prescription registers, which were individually linked to hospital records in the national patient registers and demographic and clinical data in the medical birth registers. Group-based multi-trajectory modeling (GBMTM) was used to identify pregnancy clusters and typical mono- or polytherapy medication use trajectories until delivery.
resultsAmong 339 MG pregnancies, 201 (59%) used some MG medication during pregnancy or 1 year before. Four distinct multi-drug trajectories were identified: 'Intermittent users,' 'Persistent symptomatic-only users,' 'Immunosuppressant plus symptomatic users,' and 'Immunosuppressant-only users.' Most symptomatic medication users remained on a stable medication use trajectory during pregnancy. Increased use of OCS was overall rare, but occurred in around 10% of "Intermittent users". 'Immunosuppressant-only users' had stable OCS use throughout the study period and frequent non-MG hospital contacts, but rarely contacts due to MG. Although MG-related admissions were infrequent overall, they were consistently higher among 'Immunosuppressant plus symptomatic users'. Further, 'Immunosuppressant plus symptomatic users' often discontinued NSIST during pregnancy.
interpretationMost patients had no, low, or stable medication use throughout pre-pregnancy and pregnancy. Medication use trajectories discriminated MG patients with similar phenotypes and distinct healthcare utilization patterns. Such subgroups likely represent distinct disease courses in relation to pregnancy which could help in the development of individualized care pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.